A Callout for International Collaboration. Reply to Giger, E.V.; Tilen, R. Comment on “Shaniv et al. Neonatal Drug Formularies—A Global Scope. Children 2023, 10, 848”-Reference-Cited by-同舟云学术

A Callout for International Collaboration. Reply to Giger, E.V.; Tilen, R. Comment on “Shaniv et al. Neonatal Drug Formularies—A Global Scope. Children 2023, 10, 848”

Published:2023-11-13 Issue:11 Volume:10 Page:1803
ISSN:2227-9067
Container-title:Children
language:en
Short-container-title:Children

Author:

Shaniv Dotan¹²^ORCID,Smits Anne³⁴^ORCID,Allegaert Karel³⁵⁶^ORCID,

Affiliation:

1. Pharmacy Services, Kaplan Medical Center (Clalit Health Services), Pasternak St., P.O. Box 1, Rehovot 76100, Israel

2. Neonatal Intensive Care Unit, Kaplan Medical Center (Clalit Health Services), Pasternak St., P.O. Box 1, Rehovot 76100, Israel

3. Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium

4. Neonatal Intensive Care Unit, University Hospitals Leuven, 3000 Leuven, Belgium

5. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium

6. Department of Hospital Pharmacy, Erasmus MC, 3015 GD Rotterdam, The Netherlands

Abstract

We are very grateful that the global-scope paper on neonatal drug formularies has received a relevant amount of interest from the readership of the journal [...]

Publisher

MDPI AG

Subject

Pediatrics, Perinatology and Child Health

Link

https://www.mdpi.com/2227-9067/10/11/1803/pdf

Reference6 articles.

1. Shaniv, D., Bolisetty, S., Young, T.E., Mangum, B., Ainsworth, S., Elbers, L., Schultz, P., Cucchi, M., de Wildt, S.N., and van der Zanden, T.M. (2023). Neonatal Drug Formularies—A Global Scope. Children, 10.

2. Giger, E.V., and Tilen, R. (2023). Comment on Shaniv et al. Neonatal Drug Formularies—A Global Scope. Children 2023, 10, 848. Children, 10.

3. Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates;Ward;Pediatr. Res.,2017

4. Benefit-Risk assessment of off-label drug use in children: The Bravo framework;Mooij;Clin. Pharmacol. Ther.,2021

5. Working group neonatal pharmacology (NeoDose project);Allegaert;Neonatology,2023